Posters

Retinal image quality after 1,4mm BIMICS and 1,8mm BIMICS surgery with implantation of MJ14 modern MICS IOL

Poster Details

First Author: P. Klonowski POLAND

Co Author(s):    A. Prokopiuk   J. Mackiewicz   R. Rejdak              

Abstract Details

Purpose:

Trend to diminish cataract surgery incision size is limited only by IOL technology. IOL optic efficiency is correlated with compression and decompression during implantation. The purpose of this study is to evaluate aberrometry and retinal image quality after bi-MICS cataract surgery with incision size of 1.4 mm and 1.8 mm with implantation INCISE MJ14 MICS IOL.

Setting:

Department of General Ophthalmology Medical University of Lublin, Poland Department of Vitreoretinal Surgery Medical University of Lublin, Poland

Methods:

Cataract surgery was performed with bi-MICS approach. Patients were involved to two groups: 1.4mmMICS and 1.8mmMICS incision. Aberration measurement data and Strehl ratio were obtained from Topcon KR-9000PW wave-front analyser.

Results:

The study enrolled 20 cases of 1.4mm bi-MICS eye surgery and 20 cases 1.8mm bi-MICS eye surgery with implantation MJ14 IOL. Three months after surgery BCDVA for 1.8MICS was 0,95 ± 0,10 and BCDVA for 1.4MICS was 1,02 ± 0,14. There was no increase of the total eye’s HOA and corneal aberrations were mostly stable, however, we noticed increase of spherical aberrations in the 1.8mm MICS group. Strehl ratio for 1.8MICS was 0,21 and for 1.4 MICS was 0.22

Conclusions:

Refractive results of the implantation MJ14 IOL with Bi-MICS technology are engaging and lead to fast visual recovery of the patients. We did not observe any lens related complications. We can conclude that MICS surgical technique mostly does not increase corneal aberrations and SIA. Implantation of the new MICS IOL MJ14 does not increase total eye’s HOA. It seems that 1.4mm MICS is an appropriate technique for cataract surgery with this type of IOL because of corneal neutrality and good lens performance.

Financial Disclosure:

One or more of the authors receives nonNONEmonetary benefits from a company producing, developing or supplying the product or procedure presented.